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Serum has been known to stimulate collagen pro-
duction by dermal ®broblasts. As part of an ongoing
study of the molecular mechanisms of collagen pro-
duction, we have investigated transcriptional regula-
tion of the human a2(I) collagen gene by serum in
human dermal ®broblasts. Serum responsive elem-
ents were mapped by deletion analysis between bp
±353 and ±264, and between ±148 and ±108 in the
a2(I) collagen promoter. Further functional analysis
of the a2(I) collagen promoter containing various
substitution mutations revealed that serum stimula-
tion of this promoter is mediated equally by a GC-
rich region located between bp ±303 and ±271 and by
the TCCTCC motif located between bp ±123 and
±128, both of which constitute binding sites for tran-
scription factor Spl and Sp3. No differences were
observed in electrophoretic mobility shift assays
between unstimulated and serum stimulated ®bro-
blasts. The Spl inhibitor mithramycin blocked stimu-
lation of the a2(I) collagen promoter activity by
serum. Furthermore, immunoprecipitation analysis
showed that serum stimulation increased Spl phos-
phorylation. In conclusion, this study characterized
response elements that mediate serum stimulation of
the human a2(I) collagen promoter and suggests that
serum stimulation was mediated via Sp1/Sp3 bind-
ing sites in this promoter. Key words: cytokines/dermal
®broblasts/gene regulation/transcription factors. J Invest
Dermatol 117:301±308, 2001
C
ollagen type I, the most abundant mammalian
collagen, consists of two a1(I) and one a2(I) chain,
which are coordinately expressed (Ramirez and
DiLiberto, 1990; Vuorio and de Crombrugghe,
1990). The expression of type I collagen is strictly
regulated during development and is tissue-speci®c (Ramirez and
DiLiberto, 1990). Excessive deposition of type I collagen is
characteristic of many ®brotic disorders (Bornstein and Sage,
1980) and most likely results from transcriptional activation of
collagen genes in response to cytokines and other factors present in
the pre®brotic/in¯ammatory lesions.
Initial studies of the human a2(I) promoter have indicated that
the ±376 to ±108 bp promoter segment is suf®cient to direct a high
level of transcription in human ®broblasts (Boast et al, 1990);
however, transcriptional regulation of this promoter in human
®broblasts differs in some respects from transcriptional regulation of
the murine a2(I) collagen promoter. For example, it has been
demonstrated that CTF/NF1 does not bind to the human a2(I)
collagen promoter (Inagaki et al, 1994). Transforming growth
factor (TGF)-b stimulation of the human a2(I) collagen promoter
is mediated by a multiprotein complex that interacts with two
distinct promoter segments (±330 to ±286 and ±271 to ±255)
termed TbRE (Inagaki et al, 1994). The proteins in this complex
have been identi®ed as transcription factors Sp1 and Sp3 (Tamaki et
al, 1995; Ihn and Trojanowska, 1997). Interestingly, TbRE also
mediates inhibitory effects of tumor necrosis factor-a on transcrip-
tional regulation of the human a2(I) collagen promoter (Inagaki et
al, 1995). In addition, a GC-rich region containing Sp1/Sp3
binding sites mediates basal activity of the human a2(I) collagen
promoter (Tamaki et al, 1995; Ihn and Trojanowska, 1997). Two
other studies have also suggested that AP1 family members are
involved in mediating TGF-b effects in the mouse and human
a2(I) collagen promoter (Chang and Goldberg, 1995; Chung et al,
1996).
We have identi®ed three other responsive elements in the
downstream promoter region (Ihn et al, 1996). These regions
include sequences from bp ±173 to ±155 (footprint I), ±133 to ±119
(footprint II), and ±101 to ±72 (footprint III). A novel positive cis-
element containing a TCCTCC motif was identi®ed within
footprint II, which is a binding site of the transcription factors Sp1
and Sp3 (Ihn et al, 1996, 1997). We have also demonstrated that
this TCCTCC motif is the oncostatin M responsive element of the
human a2(I) collagen gene (Ihn et al, 1997). A pyrimidine-rich
region that contains TCCCCC motif within footprint I was
demonstrated to constitute a binding site for a transcriptional
repressor, which was also shown to be a binding site for Sp1 and
Sp3 (Ihn et al, 1996; Ihn and Trojanowska, 1997). Furthermore, a
CCAAT motif within footprint III was determined to be a binding
site for transcriptional activator, CBF homolog (Ihn et al, 1996;
Collins et al, 1997).
Serum is one of the most important factors affecting the growth
and synthetic activities of cells during in¯ammation, injury, wound
repair, and regeneration of connective tissues. In particular, serum
stimulates the production of collagens and other proteins by human
diploid ®broblasts (Narayanan and Page, 1977, 1983, 1987). A
previous study demonstrated that serum increases type I collagen
production correlated with enhanced mRNA levels, and that serum
regulation of type I collagen synthesis occurs primarily at the
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transcriptional level (Narayanan et al, 1987). In this study, we have
investigated the mechanism of the human a2(I) collagen stimula-
tion by serum in dermal ®broblasts.
MATERIALS AND METHODS
Reagents Fetal bovine serum (FBS) was purchased from Gibco BRL
(Rockville, MD), mithramycin and 1-(5-isoquinolinesulfonyl)-2-
methylpiperazine (H7) were obtained from Sigma (St Louis, MO), and
okadaic acid was purchased from Upstate Biotechnology (Bedford, MA).
Cell culture Human dermal ®broblasts derived from a 2-mo-old
child (GM05756A) were obtained from Coriell Cell Repositories
(Camden, NJ) and propagated in Dulbecco's minimal Eagle's medium
(DMEM) supplemented with 10% FBS. Human adult dermal ®broblasts
were obtained from healthy volunteers, following institutional approval
and informed consent. Primary explant cultures were established in
25 cm2 culture ¯asks in DMEM supplemented with 10% FBS, 2 mM L-
glutamine and 50 mg amphotericin per ml. Fibroblast cultures
independently isolated from different individuals were maintained as
monolayers at 37°C in 90% air, 10% CO2, and studied between the
third and sixth subpassages. Cell viability was determined by trypan blue
stain (Gibco BRL).
Plasmid constructions The deletion and substitution mutant
plasmids have been previously described (Ihn et al, 1996, 1997).
Substitution mutations were generated using Quick Change site-directed
mutagenesis kit (Stratagene) and con®rmed by sequencing. Plasmids used
in transient transfection assays were twice puri®ed on CsCl gradients. At
least two different plasmid preparations were used for each experiment.
Transient transfections and chloramphenicol acetyltransferase
(CAT) assays Human ®broblasts were grown to 90% con¯uence in
100 mm dishes in DMEM with 10% FBS. Monolayers were washed, and
cells were transfected by the calcium phosphate technique (Ihn et al,
1996) with 20 mg of various deletion or mutant promoter±CAT
constructs. pSV-b-galactosidase control vector (Promega, Madison, WI)
was cotransfected to normalize for transfection ef®ciency. After
incubation overnight, the medium was replaced with DMEM containing
0.1% bovine serum albumin or with DMEM containing 10% FBS, and
incubation was continued for 48 h. Cells were harvested in 0.25 M Tris-
HCl (pH 8) and fractured by freeze thawing. Extracts, normalized for
protein content as measured by the Bio-Rad reagent, were incubated
with butyryl-CoA [14C]chloramphenicol for 90 min at 37°C. Butyrated
chloramphenicol was extracted using an organic solvent (2:1 mixture of
tetramethylpentadecane and xylene) and quantitated by scintillation
counting. Each experiment was performed in duplicate. In order to
normalize for small variations in transfection ef®ciencies, the data were
standardized with b-galactosidase activity using a b-Galactosidase Enzyme
Assay System (Promega). The Mann±Whitney U test was used to
determine statistical signi®cance.
Preparation of nuclear extract Nuclear extracts were prepared as
described previously (Andrews et al, 1991; Ihn et al, 1996). Brie¯y,
con¯uent cells from ®ve 150 mm dishes were washed with phosphate
buffer saline (PBS) and scraped into 1 ml of cold buffer A (10 mM
HEPES-KOH pH 7.9 at 4°C, 1.5 mM MgCl2, 10 mM KCl, 1 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl ¯uoride, 1 mM sodium
orthovanadate). The cells were allowed to swell on ice for 10 min and
then vortexed for 10 s. After centrifugation for 3 min, the supernatant
was discarded. The pellet was resuspended in 80 ml of cold buffer C
(20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM ethylenediamine tetraacetic acid) and incubated on ice
for 20 min for high salt extraction. Cellular debris was removed by
centrifugation for 2 min at 4°C and the supernatant fraction was stored
at ±80°C until use. The protein concentration of the extract was
determined using the Bio-Rad reagent.
DNA mobility shift assays DNA mobility shift assays were
performed as described (Ihn et al, 1997). Radioactive probes (132-mer)
were generated by polymerase chain reaction using [g-32P]adenosine
triphosphate end-labeled primers or direct end-labeling of
oligonucleotide probes. For DNA mobility shift assay, the binding
reaction was carried out for 30 min in 20 ml of binding buffer containing
10 000 cpm of labeled probe, 2 mg of poly(dI-dC)poly(dI-dC), and
nuclear extracts containing 5 mg of protein. Where indicated, speci®c
synthetic oligonucleotides or antibodies were included in the reaction
mixture. Separation of free radiolabeled DNA from DNA±protein
complexes was carried out on a 5% nondenaturing polyacrylamide gel in
a 0.5 3 Tris borate electrophoresis buffer at 200 V at 4°C.
Autoradiography was performed by overnight exposure to Kodak
XOMAT ®lm with intensifying screens at ±80°C. The densities of bands
were measured using a phosphoimager scanner.
RNA preparation and northern blot analysis Fibroblasts were
grown to con¯uence in DMEM supplemented with 10% FBS and then
incubated for 24 h in serum free medium (DMEM plus 0.1% bovine
serum albumin) before addition of serum. Total RNA was extracted and
analyzed by northern blotting as described previously (Ihn et al, 1997).
Filters were sequentially hybridized with radioactive probes for a2(I)
procollagen, Sp1, Sp3 and glyceraldehyde-3-phosphate dehydrogenase.
The ®lters were scanned with a Phosphoimager (Molecular Dynamics,
Sunnyvale, CA).
Western blot analysis Nuclear extract (15 mg) was electrophoresed
in 7.5% sodium dodecyl sulfate-polyacrylamide gel and transferred on to
nitrocellulose ®lters and probed with anti-Sp1 or anti-Sp3 antibody
(Santa Cruz) as described previously (Ihn and Trojanowska, 1997). Then
the ®lters were incubated for 30 min with horseradish peroxidase-
conjugated goat antirabbit IgG. Sp1 and Sp3 were detected using an
enhanced chemilunescent system (Amersham) according to the
manufacturer's recommendations. The densities of bands were measured
using densitometer.
Immunoprecipitation Fibroblasts were washed three times with
PBS and scraped into 500 ml of lysis buffer (50 mM Tris-HCl pH 8.0 at
4°C, 150 mM NaCl, 2 mM ethylenediamine tetraacetic acid, 50 mM
NaF, 1% Triton X-100, 1% NP-40, 1 mM phenylmethylsulfonyl
¯uoride, 1 mM sodium orthovanadate, 1 mg each of aprotinin, leupeptin,
and pepstein per ml). The cells were incubated at 4°C for 30 min with
rotation. After centrifugation for 15 min, the supernatant was transferred
to a fresh microcentrifuge tube and the extract was precleared with 20 ml
of protein A-sepharose for 1 h with rotation. The beads were pelleted,
Figure 1. Serum induces concentration-dependent increase in
promoter activity of the human a2(I) collagen gene. The plasmid
carrying the ±3500 kb fragment of the human collagen promoter
sequence cloned upstream from the CAT reporter gene was transiently
transfected into human ®broblasts as described under Materials and
Methods. On the day after transfection, some dishes were incubated with
various concentrations of serum or 3 ng TGF-b per ml without serum
for 24 h, whereas control dishes received medium only. Comparisons of
promoter activity in response to serum were made between unstimulated
and serum- stimulated promoter activities. Asterisks indicate statistically
signi®cant results (p < 0.01).
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the supernatant was transferred to a new tube, and 20 m1 of protein A-
sepharose beads conjugated to Sp1-speci®c antibody was added.
Immunoprecipitation was performed overnight at 4°C with rotation,
after which the immunoprecipitated proteins were washed four times
with lysis buffer. At the last wash, the beads were transferred to a new
tube, resuspended in 30 ml of sample buffer, and boiled for 5 min. The
samples were separated by 7.5% sodium dodecyl sulfate-polyacrylamide
gel and transferred on to nitrocellulose ®lters and probed with anti-Sp1
(Santa Cruz) or antiphosphoserine speci®c antibody (Zymed
Laboratories). Sp1 and serine-phosphorylated Sp1 were detected in the
same ®lters using an enhanced chemilunescent system as described above.
RESULTS
Serum upregulates transcriptional activity of the human
a2(I) collagen gene expression Previous studies have shown
that serum regulates collagen synthesis at the transcriptional level
(Narayanan and Page, 1977, 1987). To investigate the effect of
serum on the transcriptional activity of the human a2(I) collagen
gene, we tested the 3.5 kb fragment of the human a2(I) collagen
promoter linked to the CAT reporter gene in transient transfection
assays. Serum induced a concentration-dependent increase in
promoter activity of the a2(I) collagen gene, with maximum
stimulation observed at 10% (Fig 1). Serum stimulation resulted in
an up to 6-fold induction of promoter activity. The potency of
serum was greater than that of TGF-b under similar culture
conditions (Fig 1).
Functional mapping of the serum response element in the
a2(I) collagen promoter To analyze the transcriptional
regulation of the collagen gene by serum, we tested a series of
5¢-deletions of the human a2(I) collagen promoter linked to the
chloramphenicol acetyltransferase reporter gene in transient
transfection assays (Fig 2). Deletions to bp ±353 did not
signi®cantly alter the level of inducibility, but further deletion to
bp ±264 abolished by half the serum stimulation. Subsequent
deletion to bp ±148 had no additional effect on serum stimulation,
but deletion up to bp ±108 abolished serum stimulation completely.
Deletion of the GC-rich element (a Sp1/Sp3 binding site) between
bp ±353 and ±264 signi®cantly decreased not only basal promoter
activity (Tamaki et al, 1995) but also serum stimulation. Deletion to
bp ±148 increased promoter activity about 2.8-fold compared with
the deletion to ±186. These results further con®rmed the location
of the previously mapped repressor site between bp ±164 and ±159
(Ihn et al, 1996). Subsequent deletion to bp ±108 caused a decrease
in basal promoter activity as well as serum induction. These effects
most likely result from the removal of the previously identi®ed
positive constitutive cis-element containing a TCCTCC motif
(another Sp1/Sp3 binding site) located between bp ±128 and ±123
in this promoter (Ihn et al, 1997). As deleting between bp ±353 and
±264, or between bp ±148 and ±108 promoter fragment abolished
by half the serum response, we tested whether these cis-elements
also decrease the serum stimulation of collagen promoter activity
using substitution mutants in the GC-rich element and/or the
TCCTCC motif. As shown in Fig 3, collagen promoter constructs
carrying substitution mutations in the TCCTCC motif or the three
GC boxes abolished half the serum response. Double mutations in
the TCCTCC motif and the three GC boxes were unresponsive to
serum stimulation. Furthermore, none of the substitution mutations
in other response elements previously identi®ed in this promoter
affected serum stimulation (Fig 3).
As previously reported, the GC-rich element contains three
GC boxes that contribute the basal transcriptional activity of the
collagen promoter (Tamaki et al, 1995; Ihn et al, 1996; Ihn and
Trojanowska, 1997). We have tested the effects of the
mutations in the individual GC boxes on serum stimulation.
Mutating the individual GC boxes did not have an appreciative
effect on serum stimulation (Fig 4). A signi®cant decrease in
the promoter activity was observed with a double mutant of the
second and third GC boxes, and almost half of the serum
Figure 2. Functional mapping of the serum response elements in
the a2(I) collagen promoter. Plasmids containing various lengths of
the a2(I) collagen promoter sequence cloned upstream from the CAT
reporter gene were transiently transfected into human ®broblasts. On the
day after transfection, some dishes were incubated with 10% serum in
DMEM for 24 h, whereas control dishes received medium only.
Relative CAT activity indicates the human a2(I) collagen activity
relative to untreated cells (serum free), whose value was set at 100. The
diagrams on the left show the deletion end-points. The numbers on the
right show the basal and serum-stimulated promoter activities of each
deletion construct relative to ±353 promoter, whose value was set at 100.
The mean 6 SE values for separate experiments are also shown. The
number of experiments used to calculate the mean is shown in
parentheses. Comparisons of promoter activities in response to serum
were made between unstimulated and serum-stimulated promoters
separately for each deletion construct. Asterisks indicate statistically
signi®cant results (p < 0.001).
Figure 3. The GC boxes and the TCCTCC motif mediate serum
stimulation of the human a2(I) collagen promoter. Plasmids
carrying substitution mutations (Ihn et al, 1996) were used in transient
transfections of cells stimulated with 10% serum/DMEM. Sequences
with the mutated nucleotides are shown on the left. The stimulation
ratio for serum is shown on the right. The mean 6 SE for separate
experiments are shown. The number of experiments used to calculate
the mean is shown in parentheses. Comparisons were made between
untreated and serum treated cells. Asterisks indicate statistically signi®cant
results (p < 0.001).
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stimulation was abolished by mutating all three GC boxes
(Fig 4).
Serum stimulation does not affect nuclear protein binding
to the GC-rich element or the TCCTCC motif in the
collagen promoter To determine whether DNA±protein
interactions in these regions are regulated by serum, we
performed DNA mobility shift assays using the promoter
fragment from bp ±313 to ±183 or bp ±135 to ±116 and nuclear
extracts from human ®broblasts treated with serum up to 24 h. As
shown in Fig 5(A, B), no changes in the DNA±protein complexes
were observed in either of these regions. Furthermore, no changes
in the DNA±protein complexes were observed even after the
treatment with serum for 12 h or 24 h (data not shown).
To further determine the nature of the nuclear proteins
interacting these regions, we performed gel shift analyses with
competitor oligonucleotides or antibodies against Sp1 or Sp3. As
shown in Fig 5(C), collagen promoter fragment from ±313 to ±183
binds Sp1 and Sp3. Anti-Sp1 antibody supershifted the upper
complex (lane 3) and anti-Sp3 antibody speci®cally interferes
formation of the middle complex (lane 4), as demonstrated
previously (Ihn and Trojanowska, 1997). Simultaneous addition
of the anti-Sp1 and anti-Sp3 antibodies abolished formation of
these complexes (lane 5). Addition of IgG did not affect formation
of the DNA±protein complex (lane 6). TCCTCC motif located
between bp ±128 and ±123 also binds Sp1 and Sp3 (Fig 5D). Five
DNA±protein complexes were detected when gel shift assays were
performed with TCCTCC motif and nuclear extracts. The same
complex formation pattern has been shown before and three upper
complexes can be competed off by unlabeled speci®c competitor
oligonucleotide (Fig 5D, lane 1), but not by random sequences
(Ihn et al, 1997). The forth complex may represent nonspeci®c
binding of the proteins to this promoter region, because this
complex was competed off by random sequences (Ihn et al, 1997)
and appeared variably (Ihn et al, 1996). Addition of the anti-Sp1
antibody caused the upper complex to be supershifted (Fig 5D,
lane 2). Addition of the anti-Sp3 antibody prevented formation of
the second and the third complexes speci®cally (lane 4), as
demonstrated previously (Ihn and Trojanowska, 1997; Ihn et al,
1997). These results suggest that Sp1 and Sp3 interact with these
regions.
Furthermore, serum stimulation did not affect protein binding to
other regions of the collagen promoter: a longer collagen promoter
segment from bp ±313 to ±109 was used in DNase I protection and
DNA mobility shift assays, and there was no difference in binding
patterns between serum-stimulated and control extracts (data not
shown).
Serum stimulation does not affect mRNA or protein
synthesis of the transcription factor Sp1 or Sp3 We
reported that both the GC-rich element and the TCCTCC
motif constitute binding sites for the transcription factors Sp1 and
Sp3 (Ihn et al, 1997; Ihn and Trojanowska, 1997). Therefore, we
investigated the effect of serum on mRNA or protein synthesis of
Sp1 and Sp3. As shown in Fig 6(A), serum does not affect mRNA
levels of Sp1 or Sp3 (1.1 6 0.2-fold, 0.9 6 0.3-fold, respectively).
As shown in Fig 6(B), immunoblot analysis revealed that serum
does not affect protein levels of Sp1 or Sp3 (1.2 6 0.3-fold,
1.1 6 0.2-fold, respectively).
Mithramycin blocks serum stimulation of the human a2(I)
collagen gene expression Mithramycin is known as a speci®c
Figure 4. Effect of serum on the GC-box region. The a2(I)
collagen promoter construct carrying substitution mutations in the GC
boxes located between ±310 and ±270 were transfected into human
®broblasts with or without serum stimulation. Mutated GC boxes are in
black. Asterisks indicate statistically signi®cant results (p < 0.001).
Figure 5. Serum treatment does not change DNA-protein
binding in the human collagen promoter. Representative results of
DNA mobility shift assays. Nuclear extracts were prepared from human
®broblasts that had been either incubated in serum free medium (lane 2)
or stimulated with 10% FBS for the indicated time (lanes 3±5) up to 24
h and used in binding reactions with 5¢-end-labeled collagen promoter
fragment bp ±313 to bp ±183 (A) or bp ±135 to ±116 (B) probe as
described under Materials and Methods. Lane 1 contains no nuclear
extract. (C) Gel shift analyses were performed with 5¢-end-labeled
collagen promoter fragment bp ±313 to bp ±183 with or without anti-
Sp1 or anti-Sp3 antibodies. Lane 1 contains no nuclear extract. (D)Gel
shift analyses were performed with 5¢-end-labeled collagen promoter
fragment bp ±135 to ±116 in the absence (lane 3) or the presence of
wild-type competitor (lane 1), anti-Sp1 antibodies (lane 2), anti-Sp3
antibodies (lane 4), or IgG (lane 5).
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inhibitor of Sp1 binding (Blume et al, 1991). First, the effect of
mithramycin on the binding of Sp1 and Sp3 to the a2(I) collagen
promoter, gel shift analyses were performed using nuclear extracts
with or without addition of mithramycin. As shown in Fig 7(A),
mithramycin abolished the binding of Sp1 to the collagen
promoter, but not the binding of Sp3. Therefore, this reagent
was used to determine the role of Sp1 in serum stimulation of a2(I)
collagen promoter activity. Consistent with the reported role of
Sp1 in maintaining constitutive expression of the human a2(I)
collagen gene (Ihn and Trojanowska, 1997), mithramycin
treatment decreased basal promoter activity of the human a2(I)
collagen gene up to 40% (Fig 7B). Serum stimulation of this
promoter activity was abolished in a concentration-dependent
manner. Furthermore, serum stimulation of the human a2(I)
collagen mRNA expression was also abolished by mithramycin in a
concentration-dependent manner (Fig 7C). These results suggest
that Sp1 is involved in serum stimulation of the human a2(I)
collagen expression.
H7, a serine/threonine kinase inhibitor, abolishes serum
stimulation of the human a2(I) collagen promoter
activity Recent studies showed that serum increases Sp1
phosphorylation due to serine phosphorylation (Alroy et al, 1999;
Black et al, 1999). H7 is known as a speci®c serine/threonine kinase
inhibitor. This reagent was used to determine that serine
phosphorylation is involved in serum response. As shown in
Fig 8(A), H7 treatment abolished serum response in a
concentration-dependent manner; however, okadaic acid, a
speci®c serine/threonine phosphatase inhibitor, did not affect
serum response (Fig 8B).
Serum stimulation increased Sp1 phosphorylation in dermal
®broblasts Sp1 phosphorylation was assessed in human dermal
®broblasts following serum stimulation using immunoprecipitation.
Serine phosphorylation was determined using anti-phosphoserine
speci®c antibody. As shown in Fig 9, serum stimulation of
®broblasts led to an increased Sp1 phosphorylation (2.7 6 0.5-
fold, n = 4), whereas Sp1 levels were not affected. Furthermore,
H7 abolished increased Sp1 phosphorylation by serum (Fig 9, lane
3). Serum stimulation of ®broblasts led to an increased Sp1 serine
phosphorylation in a concentration-dependent manner, which was
maximum at 10% (data not shown).
DISCUSSION
Several cytokines have been reported to be important modulators
of collagen synthesis in human dermal ®broblasts. TGF-b (Rossi et
al, 1988), OSM (Ihn et al, 1997), interleukin-4 (Postlethwaite et al,
1992), and serum (Narayanan et al, 1997) upregulate collagen
production, whereas interferon-g (Kahari et al, 1990), TNF-a
(Kahari et al, 1990), and interleukin-10 (Reitamo et al, 1994)
downregulate it. Previous studies have characterized response
elements of these cytokines in the human a2(I) collagen promoter.
TGF-b and TNF-a have been shown to share the same response
element of this promoter, which was mapped between bp ±378 and
±255 containing three Sp1 binding sites and CCAAT/enhancer-
binding proteins binding sites (Inagaki et al, 1994, 1995; Greenwel
et al, 1997, 2000). In a different study, however, TGF-b and TNF-
a response element was mapped to a bp ±265 to ±241 region that
contains an AP-1 binding site and an nuclear factor-KB binding site
(Chung et al, 1996; Kouba et al, 1999). The reason for the
discrepancy between these studies is presently not clear. We
characterized an OSM response element in the human a2(I)
collagen promoter that is the Sp1/Sp3 binding site located between
bp ±128 and ±123 (Ihn et al, 1997). The response element
mediating modulation of a2(I) collagen promoter activity by other
cytokines has not been reported.
In this study, we have characterized serum response elements in
the human a2(I) collagen promoter, which overlap an OSM
response element and a TGF-b/TNF-a response element. We
have also shown that the serum response elements map to the same
promoter region as the previously characterized constitutive
response element (Ihn et al, 1996). Previous studies showed that
these response elements are binding sites for Sp1/Sp3 (Ihn et al,
1997; Ihn and Trojanowska, 1997). Our previous study has also
shown that constitutive activity of the human a2(I) collagen
promoter is regulated equivalently by the three positive cis-acting
elements at bp ±300 (GC-boxes), ±125 (TCCTCC motif), and ±80
(CBF binding site) (Ihn et al, 1996). Furthermore, our previous data
suggested that a repressor that binds to a promoter region located
between the GC boxes and the TCCTCC motif interferes with the
activation of the promoter via these two positive cis-elements, but
activation by the third positive response element that binds CBF
seemed to be unaffected by this repressor (Ihn et al, 1996). This
study showed that serum utilises two of the three positive response
elements of the human a2(I) collagen promoter. These results
suggest that the human collagen promoter contains multiple Sp1/
Sp3 binding sites that are also response elements of several cytokines
and that these multiple Sp1/Sp3 binding sites may be necessary to
ensure high levels of expression of this abundant protein.
Serum is a complex mixture of biomolecules that exert various
physiologic effects on dermal ®broblasts. Its major components
include various plasma proteins, peptides, lipids, carbohydrates as
Figure 6. (A) Northern blot analysis of Sp1, Sp3, and a2(I) collagen
gene expression in human dermal ®broblasts stimulated with serum.
Comparisons of Sp1, Sp3, and a2(I) collagen mRNA expression in
response to serum were made between treated and untreated cells.
Fibroblasts were treated with serum for 24 h. Representative results of
four experiments are shown. (B) Immunablot detection of Sp1 and Sp3
in human dermal ®broblasts stimulated with serum. Nuclear proteins
were electrophoresed through an 8% SDS polyacrylamide gel, transferred
to nitrocellulose membrane and probed with anti-Sp1 or anti-Sp3
antibody. Representative results of four experiments are shown. Lane 1,
nuclear extract from dermal ®broblasts untreated with serum; lane 2,
nuclear extract from dermal ®broblasts treated with serum for 24 h.
VOL. 117, NO. 2 AUGUST 2001 SERUM RESPONSE ELEMENTS IN THE HUMAN a2(I) COLLAGEN PROMOTER 305
well as growth factors and cytokines, including TGF-b. The ®rst
serum response element of the collagen promoter contains three
GC-rich motifs and overlap with a previously characterized TGF-b
response element (Inagaki et al, 1994); however, TGF-b, which is
mostly present in serum in its latent form (O'Connor-McCourt and
Wake®eld, 1987), does not seem to mediate serum response,
because a pan-speci®c TGF-b antibody (R&D Systems) did not
inhibit serum stimulation (data not shown). Moreover, TGF-b
treatment has been shown to increase binding of nuclear factors to
the ± 315±284 region (Inagaki et al, 1994), but in our study no
increase was observed after serum treatment to the same region
(Fig 5A).
The c-fos promoter has been studied extensively as a model
of growth factor regulated promoter. Serum is known to induce
the transcription of c-fos gene via the serum response element
(SRE), which is centered 310 bp upstream of the start site of c-
fos transcription (Treisman, 1985). At the SRE, a ternary
complex forms that contains serum response factor (SRF)
(Norman et al, 1988) and an Ets domain protein, ternary
complex factor (TCF), which can only bind the SRE via
interaction with SRF (Shaw et al, 1989). The TCF are
regulated by MAP kinase phosphorylation in response to
extracellular signals (Gille et al, 1992). Another transcription
factor MEF2 is also known to mediate serum induction,
especially of c-jun gene (Han and Prywes, 1995); however, the
mechanism of serum induction of c-jun gene transcription via
MEF2 is presently not clear.
In this study, serum induction of the human a2(I) collagen gene
was demonstrated to be regulated via Sp1/Sp3-binding sites. Serum
response elements of the human a2(I) collagen promoter were
mapped to Sp1/Sp3 binding sites and serum induction was blocked
by mithramycin, an inhibitor of Sp1 binding. Sp1 is a ubiquitous
transcription factor that regulates the constitutive activity of many
genes. Furthermore, several recent reports suggest that Sp1 is
involved in mediating responses to various environmental stimuli,
including epidermal growth factor stimulation of gastrin gene
(Merchant et al, 1995), and cyclic adenosine monophosphate-
dependent stimulation of the CYP11A gene (Venepally and
Waterman, 1995). Sp1 is also known to be involved in mediating
the serum signal to other genes that lack SRE (Azizkhan et al, 1993;
Xie and Herschman, 1996). In these previous studies, serum
stimulation did not affect nuclear protein binding to the response
element. In this study, serum did not affect Sp1 or Sp3 binding to
the GC-rich element or the TCCTCC motif in the human a2(I)
collagen promoter. Expression levels of transcription factors can
modulate the transcription of some genes (Kubo et al, 1995). Serum
Figure 7. Mithramycin blocks serum stimula-
tion of the human a2(I) collagen gene
expression. (A) Representative results of DNA
mobility shift assays. Nuclear extracts were
prepared from human ®broblasts that had been
either incubated without mithramycin (dimethyl
sulfoxide only, lane 1) or with mithramycin
dissolved in dimethyl sulfoxide (lane 2) and used
in binding reactions with 5¢-end-labeled collagen
promoter fragment bp ± 313 to bp ± 183. (B) The
plasmid carrying the ±353 deletion of the human
a2(I) collagen promoter was used in transient
transfections of cells stimulated with or without
10% serum/DMEM. After transfection, some
dishes were incubated with various amounts of
mithramycin, whereas control dishes received
dimethyl sulfoxide only. Cell viability was
determined by trypan blue stain. Comparisons
were made between untreated and mithramycin-
treated cells. Asterisks indicate statistically
signi®cant results (p < 0.001). (C) Northern blot
analyses of the a2(I) collagen gene in the absence
or presence of various amounts of mithramycin.
The histograms summarize the data of four
independent experiments. Asterisks indicate
statistically signi®cant results (p < 0.01).
306 IHN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
stimulation, however, does not affect mRNA or protein synthesis
of Sp1 or Sp3 in this study.
Recent studies showed that serum increases Sp1 phosphorylation
due to serine phosphorylation (Alroy et al, 1999; Black et al, 1999).
In this study, serum increases Sp1 phosphorylation also in dermal
®broblasts. Sp1 can be phosphorylated in vitro by protein kinase
CK2 (Armstrong et al, 1997), DNA-dependent protein kinase
(Jackson et al, 1990), and protein kinase A (Rohlff et al, 1997). Sp1
can be phosphorylated at multiple sites by these kinases, which are
likely to be important in regulation of its activity in response to
diverse signals.
Greenwel et al (1995) reported that tyrosine dephosphorylation
of an Sp1-containing complex induces the a2(I) collagen tran-
scription. Moreover, they also showed that H7, a serine/threonine
kinase inhibitor, abolished TGF-b1 induction of the a2(I) collagen
gene expression. In this study, H7 treatment abolished serum
response (Fig 8A), but okadaic acid did not affect serum response
(Fig 8B). These results, including ours, suggest that the signals that
induce tyrosine dephosphorylation and/or serine phosphorylation
of Sp1-containing complexes induce the a2(I) collagen transcript.
Further studies are needed to understand the signaling pathways
that regulate collagen genes.
Lack of increased levels or DNA binding of Sp1 indicates that
serum stimulation is likely to involve alterations in the association
of Sp1 with other proteins. Our previous study suggested that OSM
affects the interaction of Sp1 with histones or other chromatin
components (Ihn et al, 1997). Such a mechanism has also recently
been reported in TGF-b/TNF-a regulation of the mouse a2(I)
collagen promoter, in which cytokine treatment affected the
interaction of CTF/NF1 with histone H3 (Alevizopoulos et al,
1995; Alevizopoulos and Mermod, 1996). At this point, further
studies are needed to understand the transcriptional mechanism of
serum induction of the human a2(I) collagen gene.
In conclusion, this study characterized the cis-regulatory elem-
ents in the a2(I) collagen promoter that mediate activation of this
gene in response to serum, which are binding sites for Sp1. Both
response elements (the GC-rich element and the TCCTCC motif)
contribute equivalently to constitute expression of this gene (Ihn et
al, 1996) and each has been implicated in mediating TGF-b/TNF-
a stimulation (Inagaki et al, 1994, 1995) or in mediating OSM
stimulation (Ihn et al, 1997). The results of this study further
support a role for Sp1, the GC-rich element, and the TCCTCC
motif not only in the regulation of basal transcription of the human
a2(I) collagen gene, but also in the modulation of the expression of
this gene in response to various environmental factors.
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